 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Scientific AdvisorsGenstruct has built a world-class scientific advisory board, comprised of experts in Oncology, Metabolic Disorders, Inflammation and Systems Biology.James W. Serum, Ph.D. - SAB Chairman SAB Chairman Jim Serum is the president of SciTek Ventures. Previously, he was the executive vice president and chief operating officer of Viaken Systems, a discovery informatics company, which he co-founded after retiring from the Hewlett-Packard Company. Dr. Serum began his career at Hewlett-Packard in 1973 as an applications chemist, and held numerous R&D and Marketing management positions before being named general manager for Mass Spectrometry, Infrared and Protein Chemical Systems in 1992. Dr. Serum was the founder of Hewlett-Packard's Bioscience Products business, and served as chairman of Hewlett-Packard's Pharmaceutical Business Council. He also served as co-chairman of the Hewlett-Packard Corporate R&D Council. Additionally, Dr. Serum is a lifetime National Associate of the National Academy of Sciences, a member of the Visiting Committee for Advanced Technology at the National Institute of Standards and Technology, the President's Advisory Board at Research Corporation, and the Advisory Board of the Barnett Institute at Northeastern University. Dr. Serum received a B.A. in chemistry from Hope College and a Ph.D. in organic chemistry from the University of Colorado. to top Alan Williamson has more than 35 years in the biology field. He is a former member on the Advisory Council to NIH's U.S. National Human Genome Research Institute and the Advisory Committee for Sequencing the Human Genome. Before retiring from full-time employment, he was a professor of biochemistry at the University of Glasgow and held senior research management positions at Glaxo and Merck & Co, most recently as the vice president of Basic Research. Dr. Williamson initiated and directed the Merck Gene Index Project, and coordinated the creation of The SNP Consortium (TSC) consisting of 10 major pharmaceutical companies and the Wellcome Trust. Among other honors, Dr. Williamson is a Fulbright Scholar, Fellow of the Institute of Biology, Fellow of the Royal Society of Edinburgh and was awarded the Colworth Medal of the Biochemical Society. He has held non-executive director positions with Brax, Onconova, Oxxon Pharmacines, Solexa and Viaken Systems, and has also served on the SABs of Brax, Cambridge Healthtech Institute Genome Series, Kudos Pharmaceuticals, Sense Therapeutics, Solexa and Therapeutic Human Polyclonals. to top Josh LaBaer is the director of the Institute of Proteomics at Harvard Medical School. He attended the University of California at Berkeley as an undergraduate and completed medical school and graduate school at the University of California, San Francisco where he studied steroid regulation of DNA transcription and protein-DNA interactions. He completed his internship and residency at the Brigham and Women's Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute in Boston. He also pursued research interests at the Massachusetts General Hospital in Boston in the areas of breast cancer, mammalian cell cycle regulation and cell cycle checkpoint genes. He is currently holds an academic appointment through the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and is an attending physician at Dana-Farber Cancer Institute. He was one of the key individuals involved in the testing of the recombinational cloning system used by the institute, and became director in February 1999. Dr. LaBaer is on the Scientific Advisory Committee for the Proteome Society and a founding member of the Human Proteome Organization. to top Doug Lauffenburger is the director of the Biological Engineering [BE] Division, and professor at the Biology Department and Chemical Engineering Department at MIT. He is a member of the Center for Cancer Research, Center for Biomedical Engineering and Biotechnology Process Engineering Center as well as the Executive Committee of the MIT Computational & Systems Biology Initiative. Dr. Lauffenburger received his B.S. and Ph.D. in chemical engineering from the University of Illinois and the University of Minnesota respectively. His major research interests are in cell engineering, and central focus of his research program is in receptor-mediated cell communication and intracellular signal transduction, with emphasis on development of predictive computational models derived from quantitative experimental studies, and its application to drug discovery and development. Dr. Lauffenburger co-authored a monograph entitled “Receptors: Models for Binding, Trafficking & Signaling”, published by Oxford University Press. to top Bill Hahn is an assistant professor of Medicine at Harvard Medical School. He is a medical oncologist and cancer researcher in the Department of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Hahn attended Harvard College and then Harvard Medical School where he completed his medical training and his graduate training in molecular and cellular immunology. After his residency in Internal Medicine at the Massachusetts General Hospital, Dr. Hahn completed a clinical fellowship in medical oncology at the Dana-Farber Cancer Institute and a postdoctoral fellowship with Dr. Robert A. Weinberg at the Whitehead Institute for Biomedical Research. He is currently on the faculties of the Harvard Medical School and the Dana-Farber Cancer Institute. His current work focuses on understanding the cooperative genetic interactions that lead to malignant transformation and the creation of novel experimental model systems for the study of normal and malignant epithelial biology. Clinically, he is a member of the Lank Center for Genitourinary Oncology and is devoted to the development of new therapeutic strategies for the treatment of prostate and lung cancers. to top Atul Butte is a practicing pediatric endocrinologist and assistant professor at Stanford University. Dr. Butte received his undergraduate degree in computer science from Brown University, and has worked as a software engineer at Apple Computer and Microsoft Corporation. While pursuing his M.D. from the Brown University School of Medicine, Dr. Butte worked as a research fellow at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the Howard Hughes/NIH Research Scholars Program. Dr. Butte is an inventor on five pending U.S. patents, including one for Relevance Networks. While at Harvard, Dr. Butte received the American Association for Cancer Research / Pharmacia Scholar-In-Training Award and the Lawson Wilkins Pediatric Endocrine Society NovoNordisk Clinical Scholar Award. Dr. Butte has co-authored the first book on microarray analysis titled "Microarrays and Integrative Genomics." to top Trey Ideker is currently an Assistant Professor at the Department of Bioengineering at University of California, San Diego. Previously he was at the Whitehead Institute, where he was a Whitehead Institute/Pfizer Computational Biology Fellow. Dr. Ideker is a pioneer of system biology tools. He is developing large-scale, computer-aided models of biological signaling and regulatory pathways, which are crucial to the understanding of biological systems as more than merely the sum of their parts. Dr. Ideker received his B.S. and M.S. from MIT in electrical engineering and computer science and obtained a Ph.D. in molecular biotechnology at the University of Washington under Dr. Leroy Hood. Dr. Ideker holds several patents in the fields of microarray analysis and systems biology. to top |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |